HXBM (Helix Biomedix) Piotroski F-Score: 0 (As of Jun. 27, 2026)


What is Helix Biomedix Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Helix Biomedix has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Helix Biomedix's Piotroski F-Score or its related term are showing as below:

Helix Biomedix  (OTCPK:HXBM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Helix Biomedix Piotroski F-Score Related Terms


Helix Biomedix Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Helix Biomedix's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix Biomedix Piotroski F-Score Chart

Helix Biomedix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 2.00 2.00 5.00 1.00

Helix Biomedix Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 1.00 2.00 3.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep12) TTM:Last Year (Sep11) TTM:
Net Income was -0.548 + -0.582 + -0.668 + -0.785 = $-2.58 Mil.
Cash Flow from Operations was -0.384 + -0.525 + -0.397 + -0.512 = $-1.82 Mil.
Revenue was 0.446 + 0.68 + 0.471 + 0.469 = $2.07 Mil.
Gross Profit was 0.314 + 0.471 + 0.306 + 0.334 = $1.43 Mil.
Average Total Assets from the begining of this year (Sep11)
to the end of this year (Sep12) was
(3.432 + 2.975 + 3.049 + 2.233 + 1.702) / 5 = $2.6782 Mil.
Total Assets at the begining of this year (Sep11) was $3.43 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $1.21 Mil.
Total Current Liabilities was $0.52 Mil.
Net Income was -4.722 + -0.71 + -0.625 + -0.606 = $-6.66 Mil.

Revenue was 0.358 + 0.358 + 0.693 + 0.395 = $1.80 Mil.
Gross Profit was 0.276 + 0.237 + 0.34 + 0.267 = $1.12 Mil.
Average Total Assets from the begining of last year (Sep10)
to the end of last year (Sep11) was
(3.115 + 5.228 + 4.662 + 4.06 + 3.432) / 5 = $4.0994 Mil.
Total Assets at the begining of last year (Sep10) was $3.12 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $2.98 Mil.
Total Current Liabilities was $0.34 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Helix Biomedix's current Net Income (TTM) was -2.58. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Helix Biomedix's current Cash Flow from Operations (TTM) was -1.82. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep11)
=-2.583/3.432
=-0.75262238

ROA (Last Year)=Net Income/Total Assets (Sep10)
=-6.663/3.115
=-2.13900482

Helix Biomedix's return on assets of this year was -0.75262238. Helix Biomedix's return on assets of last year was -2.13900482. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Helix Biomedix's current Net Income (TTM) was -2.58. Helix Biomedix's current Cash Flow from Operations (TTM) was -1.82. ==> -1.82 > -2.58 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep12)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep11 to Sep12
=0/2.6782
=0

Gearing (Last Year: Sep11)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep10 to Sep11
=0/4.0994
=0

Helix Biomedix's gearing of this year was 0. Helix Biomedix's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep12)=Total Current Assets/Total Current Liabilities
=1.21/0.52
=2.32692308

Current Ratio (Last Year: Sep11)=Total Current Assets/Total Current Liabilities
=2.979/0.335
=8.89253731

Helix Biomedix's current ratio of this year was 2.32692308. Helix Biomedix's current ratio of last year was 8.89253731. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Helix Biomedix's number of shares in issue this year was 0.166. Helix Biomedix's number of shares in issue last year was 0.166. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.425/2.066
=0.68973863

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.12/1.804
=0.62084257

Helix Biomedix's gross margin of this year was 0.68973863. Helix Biomedix's gross margin of last year was 0.62084257. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep11)
=2.066/3.432
=0.60198135

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep10)
=1.804/3.115
=0.57913323

Helix Biomedix's asset turnover of this year was 0.60198135. Helix Biomedix's asset turnover of last year was 0.57913323. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+1+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Helix Biomedix has an F-score of 6 indicating the company's financial situation is typical for a stable company.


Helix Biomedix Business Description

Address 19125 North Creek Parkway, Suite 120, Bothell, WA, USA, 98011
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.